A treatment for dry eye—a burning, gritty condition that can impair vision and damage the cornea—could some day result from computer simulations that map the way tears move across the surface of the ...
With the singular exception of punctal or canalicular occlusion, when we are talking about in-office dry eye disease ...
Dry eye syndrome can cause various symptoms, including pain, stinging, and blurred vision. Over-the-counter (OTC) medications such as artificial tears and prescription eye drops can help manage ...
Aldeyra Therapeutics Inc. (NASDAQ:ALDX) said it has received a Complete Response Letter from the U.S. Food and Drug Administration rejecting its New Drug Application for reproxalap, a proposed ...
Richard Adler, MD, FACS, Assistant Professor of Ophthalmology at the Wilmer Eye Institute, Johns Hopkins Institute, and Director of Ophthalmology Services at Belcara Health, discusses the critical ...
Burning, itching, watering eyes. Few things are a bigger nuisance than irritated eyes, so it's no surprise there are so many options for dry eye relief. While various treatment options are available ...
HOUSTON – Dry eye is one of the most common eye conditions affecting around 20 million Americans. More and more people are suffering from dry eye, a condition that happens when you don’t produce ...
There are two main types of dry eye disease: evaporative and aqueous tear deficiency. Evaporative dry eye occurs when there's an imbalance or instability in the tear film, the thin layer of fluid ...
After delaying its review, the FDA has rejected Aldeyra Therapeutics’ experimental dry eye disease treatment for the third time. | After delaying its review, the FDA has rejected Aldeyra Therapeutics’ ...
Aldeyra Therapeutics Inc. ALDX shares are tumbling on Tuesday following the U.S. Food and Drug Administration (FDA) update.
Severe, chronic dry eye or dry eye disease (DED) can persist for a long time and may resist standard treatments. It can happen when tear production is low or when tear flow is blocked. Severe dry eye ...